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The need for quality assurance
It is estimated that 36.9 million people globally are living with HIV, with more than two-thirds of 
these individuals located in resource-limited regions.1 The ambitious UNAIDS 90-90-90 targets, 
aimed to end the HIV epidemic within the next 15 years, place diagnostics in a key role for 
achieving these goals: by 2020, 90% of all people living with HIV will know their HIV status; 90% 
of all HIV-positive people will receive sustained antiretroviral therapy; 90% of all people receiving 
antiretroviral therapy will achieve viral suppression.2 Recent estimates suggest that 15.8 million 
people are receiving antiretroviral therapy. With the new World Health Organization guidelines 
recommending test and treat, it is expected that 30 million people living with HIV will have access 
to treatment by 2020.3
The achievement of the 90-90-90 targets depends on the availability of tests for HIV case detection, 
including early infant diagnosis (EID) and viral load for monitoring viral suppression. CD4 
enumeration is still used for treatment initiation in many countries as they move toward the World 
Health Organization guidelines of test and treat, and plan to scale up viral load testing. However, 
access to these tests is reduced in resource-limited settings. Recent efforts aimed at improving access 
to these assays have seen a large increase in novel technologies that can be performed at the point of 
care (POC). The rollout of rapid POC tests for HIV testing and treatment initiation has significantly 
reduced the time for patients to receive results and initiate therapy.4,5 As testing is decentralised to 
hundreds of sites outside of the laboratory, and being performed by non-laboratory staff, ensuring 
test quality and accuracy of results have become key considerations in HIV programmes.6
Current point-of-care technologies for CD4, early infant 
diagnosis and viral load testing
To date, there are two approved (World Health Organization-prequalified) POC platforms for 
CD4 and two for EID, whereas POC viral load platforms are in the evaluation pipeline.7 Most of 
these POC technologies provide sample-in/answer-out diagnostic testing, making it possible for 
In 2015, UNAIDS launched the 90-90-90 targets aimed at increasing the number of people 
infected with HIV to become aware of their status, access antiretroviral therapies and ultimately 
be virally suppressed. To achieve these goals, countries may need to scale up point-of-care 
(POC) testing in addition to strengthening central laboratory services. While decentralising 
testing increases patient access to diagnostics, it presents many challenges with regard to 
training and assuring the quality of tests and testing. To ensure synergies, the London School 
of Hygiene & Tropical Medicine held a series of consultations with countries with an interest 
in quality assurance and their implementing partners, and agreed on an external quality 
assessment (EQA) programme to ensure reliable results so that the results lead to the best 
possible care for HIV patients. As a result of the consultations, EQA International was 
established, bringing together EQA providers and implementers to develop a strategic plan 
for countries to establish national POC EQA programmes and to estimate the cost of setting up 
and maintaining the programme. With the dramatic increase in the number of proficiency 
testing panels required for thousands of POC testing sites across Africa, it is important to 
facilitate technology transfer from global EQA providers to a network of regional EQA centres 
in Africa for regional proficiency testing panel production. EQA International will continue to 
identify robust and cost-effective EQA technologies for quality POC testing, integrating novel 
technologies to support sustainable country-owned EQA programmes in Africa.
Quality assurance for HIV point-of-care testing and 
treatment monitoring assays
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these tests to be performed with minimal training, outside of 
the traditional laboratory setting. Most of the devices can 
withstand extreme transport and environmental conditions, 
provide a test result in less than one hour and have data 
transmission capabilities. Some (and more are in development) 
can even operate on battery power.8
The rollout of CD4 POC devices in the last few years has 
provided us with lessons learnt in the implementation and 
quality management for POC testing. EID and viral load 
POC testing has not yet been fully implemented in the field, 
but will benefit from lessons learned from the CD4 
experience to strengthen existing quality programmes and 
ensure integration of POC testing within these programmes.
Understanding quality assurance
Quality management is the entire process supporting the 
quality of testing, while quality assurance is the planned 
activities implemented to support the quality management 
system (Figure 1).9,10 While it is highly recommended that a 
POC quality assurance plan address the entire quality 
assurance management cycle, in this report we focus on 
external quality assurance as a quality assurance activity 
relevant to POC testing, and the results serve as a strong 
indicator of laboratory quality.11
POC devices have in-built internal quality controls to monitor in 
real time the performance of an instrument and, to some extent, 
the user. If any of the controls fail, the device should not provide 
a test result. In contrast, external quality assessment (EQA), 
often used interchangeably with proficiency testing, challenges 
the testing environment and allows for an external expert body 
to examine the processes and provide remedial action.9,12,13
The three components of an effective EQA laboratory programme 
are site supervision, retesting of specimens, and proficiency 
testing.14 Supervision is integral to quality assurance and should 
be done routinely, but with minimal disruption to patient 
services. Retesting is rarely done due to costs and time constraints, 
and is especially challenging in the POC environment. Proficiency 
testing is the most widely-used approach to monitor the 
performance of the test used and the quality of testing. It involves 
blinded control material, meant to mimic patient specimens, sent 
from a reference laboratory to the testing site and results sent 
back for scoring. Participation in EQA programmes is often 
mandated for clinical laboratories performing regular testing of 
patient samples for HIV care and management.15,16
A low proficiency testing score should alert the laboratory or 
testing site that there is a problem. Often, identifying the 
exact nature of the problem, and then correcting the problem, 
is difficult, even for skilled technicians. The error can be 
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FIGURE 1: World Health Organization/US Centers for Disease Control and Prevention quality assurance cycle to improve the quality of HIV-related point-of-care testing. 
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either an instrument error or an operator error. Investigation 
and remedial action should be taken immediately to correct 
the problem before patients’ results are adversely affected.
Current external quality assessment 
schemes
A comprehensive external quality assurance programme 
consists of the following: proficiency testing panel design 
and production, EQA scheme/survey, results and reporting, 
customer service/technical support, and corrective action 
(Table 1).
An EQA survey or cycle consists of a panel of specimens 
intended to challenge or assess the testing event. EQA should, as 
far as possible, cover the entire range of tests, and the entire 
examination process, from sample reception, preparation and 
analysis to interpretation and reporting.17 The goal is to allow for 
regularity in testing that will highlight any changes or challenges 
a participant may encounter without having a long period of 
inaccurate testing going undetected. The reporting of results, as 
well as immediate corrective action to improve programmes, is 
the most critical component to any EQA programme. Reporting 
results is a major challenge in resource-limited settings due to 
various reasons that result in wasted resources and systematic 
problems going undetected. The number of specimens or 
members in each panel and frequency of EQA often varies by 
type of test and the EQA provider. Programmes often struggle to 
find an overall balance between ‘necessary’ and ‘sufficient’ in 
order to minimise costs and maximise resources.
External quality assessment for 
point-of-care CD4, early infant 
diagnosis and viral load testing
As new technologies are introduced, EQA needs to evolve to 
accommodate new testing strategies.18 In an effort to address 
the topic of quality of testing at hundreds, perhaps thousands 
of sites in a country, this section will consider what is 
necessary to ensure quality POC CD4, EID, and viral load 
testing.
Projected demands for point-of-care testing
With ‘test and treat’ and the scale up of viral load testing for 
monitoring patients, CD4 volumes are projected to remain the 
same in the short term and eventually decline as programmes 
transition to viral load testing. While POC testing for EID and 
viral load is currently not offered in some countries, planning 
for the rollout of these tests is ongoing and presents a critical 
time to develop strategies for quality assurance of these tests. To 
ensure synergies, the London School of Hygiene & Tropical 
Medicine established EQA International, bringing together 
EQA providers and implementers to develop a strategic plan for 
working with countries in Africa to establish national POC EQA 
programmes and estimate the cost of setting up and maintaining 
the programme. Members of EQA International include The 
Public Health Agency of Canada QASI programme, the US 
Centers for Disease Control and Prevention, Duke University 
External Quality Assurance Program Oversight Laboratory and 
Immunology Quality Assessment, South Africa National Health 
Laboratory Service, Zimbabwe National Quality Assurance 
Programme and Foundation Mérieux. EQA International is 
working closely with funders and implementing partners to 
remain one step ahead of the phased rollout of POC testing for 
EID and viral load in Africa.
How to deliver on the demands of quality-
assured point-of-care testing
Assuming hundreds and possibly thousands of devices will 
be placed in Africa over the next five years, EQA International, 
in consultation with national HIV programme and laboratory 
managers from countries in Africa with an interest in 
participating in EQA programmes for POC testing, agreed on 
TABLE 1: Considerations for external quality assessment programmes.
EQA Activity Considerations for EQA Programme
Proficiency Testing materials/specimens Compatible with the testing technology.
Ideally mimic the actual patient specimen as closely as possible.
Well-characterised and stable in order to reach the testing facility.
Homogenous to ensure participants in the EQA programme receive similar testing material.
Should not be cost-prohibitive.
EQA survey Multiple blinded samples provided periodically to a sufficient group of participating laboratories for robust analysis and/or 
identification (CLSI GP27-A2 27:8).12
Proficiency testing should be provided in a frequency that measures the laboratory capability.
Minimum frequency should be twice per year,15,26 while 3–4 times per year may be optimal. CD4 providers range in surveying from 
2–6 times per year with size of panels ranging just as much. EID and viral load EQA are typically provided in 2–6 panels per year. 
Results and reporting Timely reporting of results, possibly using reporting mechanisms that mimic patient reporting.
Clear concise reports, should include:
• results of reporting participant
• method of measurement (i.e. instrument used)
• target values expected for each analyte measured
• results distribution for all participants in the session, and acceptability of reported results (satisfactory/unsatisfactory)
• pass/fail.
Final EQA report compares the performance of the participant to others participating in the same programme.
Customer service/Technical support Important to the overall process and leads to improvement of participating sites.
EQA provider should provide reliable services to their customers, e.g. providing alternative innovative means for communication to 
participants in remote sites with unreliable internet access (SMS, WhatsApp).
Annual letters with calendar of EQA surveys and updates to the programme.
Corrective action Allows for the identification and correction of matters related to a variety of quality issues ranging from staff and instrument 
performance to infrastructure challenges, such as stock outs and transport issues.
Opportunity for refresher trainings.
Improved performance. 
EQA, external quality assessment; EID, early infant diagnosis.
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a work plan for the standardisation, production and 
distribution of proficiency testing panels and reporting 
mechanisms, to cover CD4, EID and viral load POC testing in 
Africa (Table 2).
External quality assessment 
technology
Ideally, EQA proficiency testing specimens can be used for both 
POC and laboratory testing. While the use of fresh whole blood 
samples most closely resembles clinical samples tested by a 
participant, if an EQA programme has several hundred 
participants or a participant base located over a wide 
geographical area, it may not be feasible to access enough 
material and distribute to participants within the time-frame 
that the material is stable and effective for proper evaluation. 
Commercially-stabilised whole blood products, while financially 
more challenging, are homogeneous and stable for weeks to 
months, which is beneficial for large EQA programmes.
Novel technologies are likely to be needed, given the volumes 
and potential logistical challenges, such as maintenance of 
sample integrity during transport. Several innovative cost-
effective applications are being explored to provide stabilised 
EQA specimens for CD4, EID and viral load testing. A major 
challenge with CD4 has been the necessity for whole blood 
and therefore stabilisers are required as a means of extending 
pre-analytic capacity for CD4 T-cell enumeration.19 
Considering POC sites, an ideal candidate would allow the 
EQA CD4 and EID specimens to remain stable for up to three 
weeks at ambient temperatures in-country.
Another innovative technology, the dried tube specimen 
(DTS) has been successfully used for EQA for HIV and 
syphilis rapid diagnostic tests and for automated viral load 
laboratory tests.20,21,22,23,24 DTS can likely be expanded for EQA 
of viral load POC tests as well as other tests. A study 
specifically looking at the relative impact of costs of 
implementing DTS EQA with the rollout of a rapid syphilis 
testing programme found the incremental costs of EQA 
relatively small and further cost reductions were possible 
through programme redesign.25
EQA sample considerations for POC CD4, viral load and EID 
programmes are summarised in Table 3. EQA International 
is working to identify robust and cost-effective EQA 
technologies for quality POC testing and integrating novel 
technologies to support sustainable EQA programmes.
Regional external quality 
assessment coordination centres
Currently, the majority of proficiency testing panels are 
procured from commercial EQA providers outside Africa. 
Shipment of proficiency testing panels to individual 
laboratories is costly and logistical challenges are frequently 
encountered.
A regional approach would allow for distribution of a well-
characterised panel of sufficient sample size to be used to 
compare performances across the region. The National 
Health Laboratory Service in South Africa is currently 
providing EQA for EID to more than 10 neighbouring 
countries. The AFRIQUALAB in Senegal supports EQA for 
CD4 and EID to more than 40 countries. The Zimbabwe 
National Quality Assurance Program is establishing a 
regional EQA centre to support CD4, EID and viral load 
testing. Finally, the African Society for Laboratory Medicine 
has recently established a network of six collaborating centres 
across Africa to strengthen laboratory medicine; these 
collaborating centres could also function as regional EQA 
centres.
A network of regional EQA coordinating centres can be set 
up to produce or procure proficiency testing materials from 
global providers, and coordinate distributions (Figure 2). 
These centres could also oversee the logistics and management 
of the EQA programme, providing timely corrective action 
and strengthening national quality assurance programmes 
and country capacity. Through technology transfer, these 
centres could produce panels at minimal cost, using locally-
sourced material.
Regional EQA coordinating centres can also support other 
programmes and services. The World Health Organization 
Regional Office for Africa has linked EQA programmes for 
their laboratory networks for influenza, malaria, meningitis, 
enterics and other diseases.26 The East African Regional 
External Quality Assessment Scheme supports EQA in five 
countries to improve the quality of essential diagnostic services 
in clinical laboratories at peripheral level. Future capacities of 
regional EQA centres could serve as biobanking facilities 
that support test performance evaluations and validations, 
TABLE 2: Proposed external quality assessment scheme for CD4, early infant 
diagnosis and viral load point-of-care testing.
Test EQA Survey EQA Panel
CD4 3× per year 2-member panel: high and 
low concentration
EID 2× per year 3-member panel: 1 negative 
and 2 positive samples
Viral load 2× per year 3-member panel: 1 
negative, 2 positives (1 high 
and 1 low)
Note: Shipments will be combined to save costs.
EQA, external quality assessment; EID, early infant diagnosis.
TABLE 3: External quality assessment sample considerations.
Sample indicators Proficiency testing source materials
Appropriate matrix Should mimic patient specimen; use locally 
sourced fresh whole blood; should be 
available in large volumes; dried tube 
specimens can be used as proficiency testing 
for viral load. 
Stable, homogeneous material Stabilising agent should not modify the 
diagnostic target molecules; should allow the 
panel to be stable for 3 weeks at ambient 
temperature. 
Appropriate concentration levels Concentrations should include clinically-
relevant levels.
Appropriate frequency of testing Consider starting with 2 surveys per year and 
increase coverage in country before increasing 
frequency. Recommendations by the 
American Association for Laboratory suggest 
that laboratories should be compared at least 
twice annually to the laboratory comparator 
for continued performance evaluation.26
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post-market surveillance, global health surveillance, and 
facilitate new test development.
Benefits of external quality 
assessment programmes
There is strong evidence to indicate that participation in EQA 
programmes significantly improves testing performance.23,26,27 
The US Centers for Disease Control and Prevention has 
developed EQA programmes to help participating laboratories 
monitor the quality of laboratory-based viral load and EID 
testing in low- and middle-income countries. In an analysis of 
the reported EQA data from more than 114 participating 
laboratories in 44 countries in the viral load programme, and 
136 participating laboratories in 41 countries in the EID 
programme, they found that with increased participation 
came increased performance.23,27 The Public Health Agency 
Canada (QASI)-Quality Management System, designed to 
work globally, optimised its programme strategies in 2009 
and immediately saw reduced error rates with their CD4 
programme as well as significant reduction in inter-laboratory 
variability resulting from continuous participation in the 
QASI-quality management system.28 QASI provides detailed, 
extensive technology transfer workshops to programme 
participants using a ‘train-the-trainer’ format, which 
significantly improves participation and performance. With 
CD4, improvements in performance of programmes can be 
directly linked to improvements in patient care.4,11
Apart from insights into the participants’ performance levels, 
EQA can also survey the overall national laboratory 
infrastructure and trace problems in processes. Examples of 
this include the sample transport network and supply chain 
management system. These two systems often go hand-in-
hand and contribute to reagents/kit stock-outs and poor 
quality of specimens. A comprehensive, coordinated EQA 
programme can identify these gaps and bring them to the 
attention of the country’s Ministry of Health and partners for 
immediate corrective action, strengthening the overall 
infrastructure of the country and thereby improving 
programmes and services. In addition, EQA programmes can 
also capture key indicators and document programme 
improvements over time.
EQA is an important tool for providing the educational 
stimulus that will improve overall performance and 
standards.29 Other quality assurance activities, such as 
training and site evaluations, can support a quality-assured 
environment.10,30 EQA also builds educational stimulus and 
promotes research capacity through technology transfer and 
trainings. The Institute of Public Health in Brussels, Belgium 
looked at EQA for malaria rapid diagnostic tests and found 
that EQA prompted educational incentives that boosted self-
confidence and credibility.31 EQA can also provide valuable 
information to programmes and manufacturers though post-
market surveillance.32 Post-market surveillance ensures that 
diagnostics continue to meet quality, safety and performance 
requirements. Often failures go unreported, but though a 
proactive EQA programme, these failures can be captured 
and reported appropriately.
Participation in an external quality assessment program 
provides many benefits and valuable data to health 
authorities (Figure 3):30,33
•	 Comparison of performance and results among different 
test sites.
•	 Collection of data across different sites.
•	 Early warning for systematic problems.
•	 Objective evidence of testing quality.
•	 Indicates areas that need improvement.
•	 Survey the use of diagnostic algorithms.
•	 Potential to build health security through surveillance 
and monitoring.
A key feature of many of these POC molecular devices is that 
they are equipped with data transmission capacities. Apart 
from monitoring the quality of tests and testing to optimise 
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supply chain management, data connectivity links data from 
diagnostic laboratories and POC test readers and devices to 
provide data on testing coverage, disease trends and timely 
information for early warning of infectious disease outbreaks.34
Looking forward: Sustainable, 
country-owned external quality 
assessment programmes in Africa
Sustainability of EQA programmes requires country ownership. 
As countries in Africa plan the scale-up of POC technologies for 
CD4, viral load and EID testing, political commitment toward 
quality should be reflected in country policies and 
implementation plans. Putting in place EQA programmes that 
can identify gaps and challenges in the testing environment and 
address them immediately to increase the efficiency of healthcare 
systems and improve patient results, are urgent priorities.
The role of implementing partners and industry in support of 
EQA and quality assurance programmes is also a strong 
consideration for the sustainability of quality-assured testing. 
Partners and industry can bring numerous resources to these 
programmes. As an example, when Zimbabwe was 
establishing their national quality assurance programme, the 
Ministry of Health brought together stakeholders as well as 
quality assurance and POC partners to share their vision for 
a coordinated national programme that would identify 
redundancies and gaps and leverage partner resources and 
commitment. This process secures a sustainable country-
owned quality assurance national policy.
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